VBL Therapeutics to Present Preclinical Data at Keystone Symposium on Liver Metabolism and Nonalcoholic Fatty Liver Disease
February 09, 2015 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, Feb. 9, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization of...
VBL Therapeutics Receives European Patent Issuance on Lecinoxoid Platform Technology
February 06, 2015 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, Feb. 6, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization of...
VBL Therapeutics Announces Ron Cohen and Philip Serlin Nominated to Board of Directors
January 20, 2015 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, Jan. 20, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization of...
VBL Therapeutics Announces Positive Phase 2a Data for VB-111 in Recurrent Thyroid Cancer
December 22, 2014 08:30 ET
|
VBL Therapeutics
TEL AVIV, Israel, Dec. 22, 2014 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization of...
VBL Therapeutics Announces Last Patient Out in Phase 2 Clinical Studies of VB-201 in Psoriasis and Ulcerative Colitis
December 15, 2014 08:30 ET
|
VBL Therapeutics
TEL AVIV, Israel, Dec. 15, 2014 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization of...
VBL Therapeutics to Present Company Overview at Upcoming Conferences
November 25, 2014 08:30 ET
|
VBL Therapeutics
TEL AVIV, Israel, Nov. 25, 2014 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization of...
VBL Therapeutics Announces Third Quarter 2014 Financial Results
November 13, 2014 07:01 ET
|
VBL Therapeutics
TEL AVIV, Israel, Nov. 13, 2014 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization of...
VBL Therapeutics to Present Interim Phase 2 Data From VB-111 in Recurrent Glioblastoma at 19th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO)
November 13, 2014 07:01 ET
|
VBL Therapeutics
-- Interim Data Suggest Improved Overall Survival in Patients Treated With VB-111 in Combination With Bevacizumab (Avastin®) --
TEL AVIV, Israel, Nov. 13, 2014 (GLOBE NEWSWIRE) -- VBL...
VBL Therapeutics to Present Interim Phase 2 Data From VB-111 in Recurrent Glioblastoma at 19th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO)
November 03, 2014 08:30 ET
|
VBL Therapeutics
TEL AVIV, Israel, Nov. 3, 2014 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization of...
VBL Therapeutics to Report Third Quarter 2014 Financial Results on November 13, 2014
November 03, 2014 08:30 ET
|
VBL Therapeutics
TEL AVIV, Israel, Nov. 3, 2014 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization of...